Gyre Therapeutics, Inc.
NASDAQ•GYRE
CEO: Dr. Han Ying Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2006-04-12
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
連絡先情報
時価総額
$686.68M
PER (TTM)
137.0
17.9
配当利回り
--
52週高値
$12.62
52週安値
$6.11
52週レンジ
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$37.20M+0.00%
直近4四半期の推移
EPS
-$0.02+0.00%
直近4四半期の推移
フリーCF
-$5.77M+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Revenue Growth Driven By Products Nine months 2025 Revenues reached $79.4M, up 2%, driven by $6.1M combined sales from Contiva® and Etorel®.
Strong Cash Position Maintained Cash and equivalents totaled $40.4M as of September 30, 2025; operations provided $6.6M cash flow for nine months.
Warrant Liability Impact Reduced Change in fair value of warrant liability decreased 65% to $2.4M gain for nine months ended September 30, 2025.
Common Stockholder Earnings Drop Net income attributable to common stockholders fell 45% to $6.8M for the nine months ended September 30, 2025.
リスク要因
Profitability Declined Significantly Net income dropped 35% to $11.2M for nine months 2025, despite 2% revenue increase.
Core Product Sales Weakness ETUARY® revenue declined $4.4M for nine months 2025 due to marketing focus shift and market uncertainty.
High Customer Concentration Risk Sinopharm accounted for 50.3% of accounts receivable as of September 30, 2025, posing credit risk concentration.
見通し
Hydronidone Trial Initiation Planned Anticipated initiation of the adaptive Phase 2/3 clinical trial for Hydronidone in the fourth quarter of 2025.
Etorel® Procurement Selection Etorel® selected in National Centralized Drug Procurement process; assessing potential impact on future operating performance.
R&D Investment Continues Committed $37.6M toward future R&D, including $12.9M for the Hydronidone program through September 30, 2025.
同業比較
売上高 (TTM)
$263.50M
$262.60M
$244.06M
粗利益率 (最新四半期)
215.9%
100.0%
100.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| ERAS | $4.22B | -31.0 | -34.5% | 11.9% |
| TERN | $4.19B | -45.2 | -30.0% | 0.3% |
| DAWN | $2.20B | -20.5 | -23.4% | 0.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
19.0%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月16日
EPS:$0.08
|売上高:$35.44M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし